サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427898

転移性がん治療薬の世界市場レポート 2024

Metastatic Cancer Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
転移性がん治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

転移性がん治療薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には4.8%の年間複合成長率（CAGR）で694億6,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、精密医療の進化、バイオマーカー主導療法の開発、リキッドバイオプシー技術の進歩、患者中心のアプローチの採用、包括的なゲノムプロファイリングの実施に起因すると考えられます。予測期間中に予想される主な動向には、併用療法の出現、ナノ医療の進歩、長期生存支援への焦点、早期介入戦略、健康の公平性とアクセスの重視の高まりなどが含まれます。これらの動向は、がん治療と治療の有効性と包括性を高めるための継続的な取り組みを反映しています。

転移性がん治療薬市場で予想される成長は、2つの重要な要因によって促進されると予想されます。まず、転移性がんの有病率の増加が市場の拡大に寄与する態勢が整っています。体の他の部分へのがんの進行性の広がりを特徴とする転移がんが増加しています。転移性がんの症例数の増加により、さまざまな種類の転移性がんを対象とした新しいがん治療薬の開発が加速しています。注目すべきことに、Journal of the National Cancer Instituteは2022年に、米国における転移性乳がん、前立腺がん、肺がん、結腸直腸がん、膀胱がん、または転移性黒色腫を抱えて暮らす人の数は、2025年までに69万人に達すると予想されていると予測しています。さらに、乳がん調査財団によると、2022年4月には乳がんが肺がんを上回り、世界で最も多く診断されたがんとなり、2021年だけで推定230万人の女性が罹患していると推定されています。統計の増加からも明らかなように、転移性がんの有病率の増加は、転移性がん治療薬市場の主要な促進要因となっています。

精密医療と個別化された治療の進化により、市場の成長がさらに促進されると予想されます。精密医療には、遺伝子構造、分子プロファイル、環境、ライフスタイルなどの要素を考慮して、個々の患者に合わせた医療と治療が含まれます。精密医療における転移性がん治療薬の利用により、患者固有の遺伝的および分子的特性に基づいてカスタマイズされた治療戦略が可能になります。このアプローチにより、ヘルスケア提供者は、特定のがんサブタイプに対して効果が期待できる標的療法を特定できるようになり、それによって治療成果が向上し、副作用が最小限に抑えられます。たとえば、2022年 10月のPersonalized Medicine Coalitionの推計では、さまざまながんやその他の健康状態を持つ個人が75,000を超える遺伝子検査キットと300の個別治療が利用できるようになることが示されています。個々の患者の特性に焦点を当てた、精密医療と個別化された治療の進化は、転移性がん治療薬市場の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の転移性がん治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • HER2阻害剤
  • 免疫チェックポイント阻害剤
  • PARP阻害剤
  • キナーゼ阻害剤
  • その他の薬物クラス
  • 世界の転移性がん治療薬市場、がん別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 乳がん
  • 肺がん
  • 肝臓がん
  • 血液がん
  • 脳腫瘍
  • 前立腺がん
  • 膵臓がん
  • その他のがん
  • 世界の転移性がん治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 免疫療法
  • ホルモン療法
  • 手術
  • その他の治療法
  • 世界の転移性がん治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 静脈内
  • 筋肉内
  • オーラル
  • 他の投与経路
  • 世界の転移性がん治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の転移性がん治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の転移性がん治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 転移性がん治療薬市場の競合情勢
  • 転移性がん治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Services Inc.
    • F. Hoffmann-La Roche AG
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 その他の大手および革新的な企業

  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Eisai Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Incyte Corporation
  • Ipsen SA
  • Seagen Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13742

Metastatic cancer therapies encompass pharmaceuticals designed to address cancer that has spread from its original site to other parts of the body. The primary objective of these medications is to target cancer cells, impeding their growth and preventing further spread.

Key categories of metastatic cancer drugs include HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. HER2 inhibitors specifically target human epidermal growth factor receptor (HER2) to obstruct the reception of growth signals in HER2-positive cancers. These inhibitors find applications in diverse cancer types, including breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Treatment modalities involve chemotherapy, immunotherapy, hormonal therapy, surgery, and various routes of administration such as intravenous, intramuscular, and oral administration. These therapies are utilized across different healthcare settings, including hospitals, specialty clinics, and others.

The metastatic cancer drugs market research report is one of a series of new reports from The Business Research Company that provides metastatic cancer drugs market statistics, including metastatic cancer drugs industry global market size, regional shares, competitors with a metastatic cancer drugs market share, detailed metastatic cancer drugs market segments, metastatic cancer drugs market trends and opportunities, and any further data you may need to thrive in the metastatic cancer drugs industry. This metastatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic cancer drugs market size has grown steadily in recent years. It will grow from $55.28 billion in 2023 to $57.68 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historic period can be attributed to several key factors, including the development of chemotherapy, advancements in targeted therapies, discoveries in immunotherapy, successful outcomes in clinical trials, and improvements in the diagnosis and staging of cancer. These elements collectively contributed to the progress and evolution of cancer treatment during the historical period.

The metastatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $69.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to the evolution of precision medicine, the development of biomarker-driven therapies, advancements in liquid biopsy techniques, the adoption of patient-centric approaches, and the implementation of comprehensive genomic profiling. Major trends expected in the forecast period encompass the emergence of combination therapies, advancements in nanomedicine, a focus on long-term survivorship support, early intervention strategies, and an increased emphasis on health equity and access. These trends reflect the ongoing efforts to enhance the effectiveness and inclusivity of cancer care and treatment.

The anticipated growth in the metastatic cancer drugs market is expected to be driven by two significant factors. Firstly, the increasing prevalence of metastatic cancers is poised to contribute to market expansion. Metastatic cancer, characterized by the advanced spread of cancer to other parts of the body, is on the rise. The growing number of metastatic cancer cases has spurred the development of novel cancer medications targeting various types of metastatic cancer. Notably, the Journal of the National Cancer Institute projected in 2022 that the number of individuals living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in the United States, is expected to reach 0.69 million cases by 2025. Moreover, breast cancer surpassed lung cancer in April 2022 as the most diagnosed cancer worldwide, with an estimated 2.3 million women affected in 2021 alone, according to the Breast Cancer Research Foundation. The increasing prevalence of metastatic cancers, as evidenced by rising statistics, is a key driver for the metastatic cancer drugs market.

The evolution of precision medicine and personalized therapies is anticipated to further propel market growth. Precision medicine involves tailoring medical care and treatment to individual patients, taking into account factors such as genetic makeup, molecular profile, environment, and lifestyle. The utilization of metastatic cancer drugs in precision medicine allows for tailored treatment strategies based on the unique genetic and molecular characteristics of patients. This approach enables healthcare providers to identify targeted therapies that are more likely to be effective against specific cancer subtypes, thereby enhancing treatment outcomes and minimizing adverse effects. For example, estimates from the Personalized Medicine Coalition in October 2022 indicated that over 75,000 genetic testing kits and 300 personalized treatments will be available for individuals with various cancers and other health conditions. The evolution of precision medicine and personalized therapies, by focusing on individual patient characteristics, is a significant driver for the metastatic cancer drugs market.

Product innovation is a prominent trend in the metastatic cancer drugs market, with major players focusing on the development of novel drugs to enhance their market positions. One noteworthy example is the conditional approval granted in the European Union in January 2021 for the drug ENHERTU (trastuzumab deruxtecan) as a monotherapy for the treatment of HER2-positive metastatic breast cancer. This approval, a collaborative effort between Daiichi Sankyo Company Limited and AstraZeneca PLC, marked a significant milestone in transforming outcomes for patients with HER2-positive metastatic breast cancer in the USA and Japan. The approval in the EU further expands the reach of this novel medicine to patients in the region, addressing the increasing cases of cancers.

Major companies in the metastatic cancer drugs market are actively involved in developing novel drugs such as ZN-A-1041, an oral breast cancer medicine. ZN-A-1041, an orally administered selective tyrosine kinase inhibitor, specifically targets the human epidermal growth factor receptor 2 (HER2) and is designed to penetrate the blood-brain barrier. This drug has demonstrated potential in treating or preventing the onset of brain metastases in HER2-positive metastatic breast cancer patients. For instance, in May 2022, F. Hoffmann-La Roche AG launched ZN-A-1041, which can cross the blood-brain barrier to treat breast tumors that have spread to the brain.

In March 2023, Pfizer Inc., a US-based pharmaceutical company, confirmed its acquisition plans with Seagen Inc. for $43 billion. This strategic move is part of Pfizer's broader strategy to expand its oncology portfolio and solidify its position as a global leader in the oncology division. The acquisition of Seagen Inc., a biotechnology company specializing in antibody-based cancer medicines, complements Pfizer's existing portfolio across solid tumors and hematologic malignancies.

Major companies operating in the metastatic cancer drugs market report are Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ipsen SA, Seagen Inc., Exelixis Inc., Zymeworks Inc., Karyopharm Therapeutics Inc., CRISPR Therapeutics AG, Fate Therapeutics Inc., CytomX Therapeutics Inc., Spectrum Pharmaceuticals Inc., Intellia Therapeutics Inc., GlaxoSmithKline PLC, Adaptimmune Therapeutics plc

North America was the largest region in the metastatic cancer drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metastatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic cancer drugs market consists of sales of drugs such as capecitabine, docetaxel, eribulin, pegylated, gemcitabine, and vinorelbine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: HER2 Inhibitors; Immune Checkpoints Inhibitors; PARP Inhibitors; Kinase Inhibitors; Other Drug Class
  • 2) By Cancer: Breast Cancer; Lung Cancer; Liver Cancer; Hematological Cancer; Brain Cancer; Prostate Cancer; Pancreatic Cancer; Other Cancers
  • 3) By Treatment: Chemotherapy; Immunotherapy; Hormonal Therapy; Surgery; Other Treatments
  • 4) By Route Of Administration: Intravenous; Intramuscular; Oral; Other Routes Of Administration
  • 5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Cancer Drugs Market Characteristics

3. Metastatic Cancer Drugs Market Trends And Strategies

4. Metastatic Cancer Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Metastatic Cancer Drugs Market Size and Growth

  • 5.1. Global Metastatic Cancer Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Metastatic Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Metastatic Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Metastatic Cancer Drugs Market Segmentation

  • 6.1. Global Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • HER2 Inhibitors
  • Immune Checkpoints Inhibitors
  • PARP Inhibitors
  • Kinase Inhibitors
  • Other Drug Class
  • 6.2. Global Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Liver Cancer
  • Hematological Cancer
  • Brain Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Other Cancers
  • 6.3. Global Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Hormonal Therapy
  • Surgery
  • Other Treatments
  • 6.4. Global Metastatic Cancer Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intravenous
  • Intramuscular
  • Oral
  • Other Routes Of Administration
  • 6.5. Global Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users

7. Metastatic Cancer Drugs Market Regional And Country Analysis

  • 7.1. Global Metastatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Metastatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Metastatic Cancer Drugs Market

  • 8.1. Asia-Pacific Metastatic Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Metastatic Cancer Drugs Market

  • 9.1. China Metastatic Cancer Drugs Market Overview
  • 9.2. China Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Metastatic Cancer Drugs Market

  • 10.1. India Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Metastatic Cancer Drugs Market

  • 11.1. Japan Metastatic Cancer Drugs Market Overview
  • 11.2. Japan Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Metastatic Cancer Drugs Market

  • 12.1. Australia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Metastatic Cancer Drugs Market

  • 13.1. Indonesia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Metastatic Cancer Drugs Market

  • 14.1. South Korea Metastatic Cancer Drugs Market Overview
  • 14.2. South Korea Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Metastatic Cancer Drugs Market

  • 15.1. Western Europe Metastatic Cancer Drugs Market Overview
  • 15.2. Western Europe Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Metastatic Cancer Drugs Market

  • 16.1. UK Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Metastatic Cancer Drugs Market

  • 17.1. Germany Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Metastatic Cancer Drugs Market

  • 18.1. France Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Metastatic Cancer Drugs Market

  • 19.1. Italy Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Metastatic Cancer Drugs Market

  • 20.1. Spain Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Metastatic Cancer Drugs Market

  • 21.1. Eastern Europe Metastatic Cancer Drugs Market Overview
  • 21.2. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Metastatic Cancer Drugs Market

  • 22.1. Russia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Metastatic Cancer Drugs Market

  • 23.1. North America Metastatic Cancer Drugs Market Overview
  • 23.2. North America Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Metastatic Cancer Drugs Market

  • 24.1. USA Metastatic Cancer Drugs Market Overview
  • 24.2. USA Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Metastatic Cancer Drugs Market

  • 25.1. Canada Metastatic Cancer Drugs Market Overview
  • 25.2. Canada Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Metastatic Cancer Drugs Market

  • 26.1. South America Metastatic Cancer Drugs Market Overview
  • 26.2. South America Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Metastatic Cancer Drugs Market

  • 27.1. Brazil Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Metastatic Cancer Drugs Market

  • 28.1. Middle East Metastatic Cancer Drugs Market Overview
  • 28.2. Middle East Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Metastatic Cancer Drugs Market

  • 29.1. Africa Metastatic Cancer Drugs Market Overview
  • 29.2. Africa Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Metastatic Cancer Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Metastatic Cancer Drugs Market Competitive Landscape
  • 30.2. Metastatic Cancer Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Metastatic Cancer Drugs Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. AstraZeneca plc
  • 31.3. Novartis AG
  • 31.4. Sanofi S.A.
  • 31.5. Bristol-Myers Squibb Company
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Eli Lilly and Company
  • 31.8. Gilead Sciences Inc.
  • 31.9. Amgen Inc.
  • 31.10. Astellas Pharma Inc.
  • 31.11. Eisai Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Incyte Corporation
  • 31.14. Ipsen SA
  • 31.15. Seagen Inc.

32. Global Metastatic Cancer Drugs Market Competitive Benchmarking

33. Global Metastatic Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Metastatic Cancer Drugs Market

35. Metastatic Cancer Drugs Market Future Outlook and Potential Analysis

  • 35.1 Metastatic Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Metastatic Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Metastatic Cancer Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer